Package Leaflet: Information for the Patient

Duvyzat® 8.86 mg/ml oral suspension

givinostat

Select your language:
(1190 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1137 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1079 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1067 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1170 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1059 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1080 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1033 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1115 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1190 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1185 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1236 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1050 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(888 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1133 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1190 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1015 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1023 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1214 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1175 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1083 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(969 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1170 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1148 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1123 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1244 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(1113 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026
(966 KBKB – PDF)
First publication 15/07/2025
Last update 14/07/2026

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Scroll to Top

You are now leaving this webpage and will be redirected to the Italfarmaco website to access pharmacovigilance services.